WASHINGTON, Oct. 25 -- In response to a federal agency request for information, the following public comment letter was submitted electronically to the regulations.gov site. October 16, 2026 Internal Revenue Service CC:PA:01:PR (Notice 2026-28) Room 5503 P.O. Box 7604 Ben Franklin Station Washington, DC 20044 Re: Comments on Notice 2026-28 and Code Section 45S Dear Sir or Madam, I write on behalf of The American Benefits Council ("the Council") to provide comments in connection with Notice 2026-28, "Guidance on the employer credit for paid more ST

WASHINGTON, Oct. 25 -- In response to a federal agency request for information, the following public comment letter was submitted electronically to the regulations.gov site. October 15, 2026 Commissioner Kyle Diamantas U.S. Food and Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993 Re: PDUFA VIII Reauthorization and Proposed Commitment Letter; Docket: FDA-2026-N-8163 Dear Acting Commissioner Diamantas, On behalf of the American Brain Coalition (ABC), thank you for the opportunity to comment on the proposed recommend more ST

WASHINGTON, Oct. 25 -- In response to a federal agency request for information, the following public comment letter was submitted electronically to the regulations.gov site. 1 October 16, 2026 Food and Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993 Re: Docket No. FDA-2026-N-8163 -- Reauthorization of the Prescription Drug User Fee Act; Comments on the Proposed PDUFA VIII Commitment Letter Dear FDA Leadership, The Rare Disease Company Coalition (RDCC) appreciates the opportunity to comment on the proposed PDUFA VI more ST